Kalentakis Zacharias, Economou Vasiliki, Maragkoudakis Pavlos
Otolaryngology - Head and Neck Surgery, Sismanoglio General Hospital of Attiki, Athens, GRC.
Biostatistics, Private Statistic Services, Athens, GRC.
Cureus. 2025 Aug 27;17(8):e91132. doi: 10.7759/cureus.91132. eCollection 2025 Aug.
There is currently no universally effective treatment for subjective tinnitus, and management strategies focus on the relief of symptoms rather than a definite cure. In line with this, our prospective, non-interventional, non-placebo-controlled, multicenter clinical study, conducted in private clinics, evaluates the efficacy of taking a daily supplement based on active compounds in alleviating tinnitus-related disability. The study was conducted in adults with tinnitus who were instructed to take one capsule daily, 30 minutes before bedtime, for a duration of three months between March 30 and December 20, 2024. This study aims to provide valuable clinical insights into the potential therapeutic benefits of a dietary supplement in alleviating the symptoms of tinnitus and improving patients' quality of life. Employing validated assessment tools, such as the Tinnitus Handicap Inventory (THI), this study seeks to provide objective evidence regarding the potential benefits of MEMOTIN® as a supportive intervention for individuals suffering from tinnitus.
目前，对于主观性耳鸣尚无普遍有效的治疗方法，治疗策略侧重于缓解症状而非彻底治愈。与此一致的是，我们在私人诊所进行的前瞻性、非干预性、非安慰剂对照的多中心临床研究，评估了服用基于活性成分的每日补充剂在减轻耳鸣相关残疾方面的疗效。该研究针对患有耳鸣的成年人开展，他们被要求在2024年3月30日至12月20日期间，每天睡前30分钟服用一粒胶囊，持续三个月。本研究旨在为膳食补充剂在减轻耳鸣症状和改善患者生活质量方面的潜在治疗益处提供有价值的临床见解。通过使用经过验证的评估工具，如耳鸣残疾评定量表（THI），本研究旨在提供客观证据，证明MEMOTIN®作为对耳鸣患者的支持性干预措施的潜在益处。
